Parameter
| Biomarker | SPARC | Full name | Secreted protein acidic and rich in cysteine | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Prognostic assessment and prediction of treatment response | ||
| Disease | Pancreatic Cancer | Disease Subtypes | / | ||
| Organ | Pancreas | Test Sample / Technology Platform | Tissue and serum (immunohistochemical, mass spectrometry) | ||
| Pathobiological Mechanisms | That is, an acidic secreted protein rich in cysteine, which is highly expressed in tumor stromal fibroblasts, participates in tumor matrix remodeling and drug delivery barrier formation, and its expression is related to the response to albumin-bound paclitaxel treatment | ||||
| Clinical Availability Status | Clinical Availability Status Clinical research phase: used for prognostic stratification and treatment selection | ||||
| Notes and Dynamics | Source of stromal SPARC is adverse prognostic markers, and high expression in patients with albumin combined with paclitaxel therapy significantly extended, the median overall survival guide markers can be used as personalized treatment | ||||